Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cluster-targeted multi-target CTL therapy in recurrent/metastatic nasopharyngeal carcinoma
ChiCTR2400082453Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and PD-1 Monoclonal Antibody in recurrent nasopharyngeal carcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoints: Accuracy of diagnosis and Progression-free survival. Started Mar 2024; status: recruiting.
02
Drugs
gemcitabinecisplatinPD-1 Monoclonal Antibody
03
Conditions
recurrent nasopharyngeal carcinoma
Beyond the preview
Go deeper on ChiCTR2400082453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082453.